In conclusion, to our knowledge, this is the first study investigating the initial changes in plasma VEGF levels for the prediction of insufficient response to therapy and disease progression in advanced NSCLC patients during first-line chemotherapy. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.